Antioxidant activity elicited by low dose of caffeine attenuates pentylenetetrazol-induced seizures and oxidative damage in rats

Neurochem Int. 2013 May;62(6):821-30. doi: 10.1016/j.neuint.2013.02.021. Epub 2013 Feb 26.

Abstract

Although caffeine supplementation has a beneficial effect on people with neurological disorders, its implications for oxidative damage related to seizures are not well documented. Thus the aim of this study was to investigate the effects of two weeks caffeine supplementation (6mg/kg; p.o.) on seizures and neurochemical alterations induced by pentylenetetrazol (PTZ 60mg/kg i.p.). Statistical analyses showed that long-term rather than single dose caffeine administration decreased the duration of PTZ-induced seizures in adult male Wistar rats as recorded by cortical electroencephalographic (EEG) and behavioral analysis. The quantification of EEG recordings also revealed that caffeine supplementation protected against a wave increase induced by PTZ. Neurochemical analyses revealed that caffeine supplementation increased glutathione (GSH) content per se and protected against the increase in the levels of thiobarbituric acid reactive substances (TBARS) and oxidized diclorofluoresceine diacetate (DCFH-DA). Also, caffeine prevent the decrease in GSH content and Na(+), K(+)-ATPase activity induced by PTZ. Our data also showed that the infusion of L-buthionine sulfoximine (BSO; 3.2μmol/site i.c.v), an inhibitor of GSH synthesis, two days before injecting PTZ reversed the anticonvulsant effect caused by caffeine. BSO infusion also decreased GSH content and Na(+), K(+)-ATPase activity. However, it increased DCFH-DA oxidation and TBARS per se and reversed the protective effect of caffeine. Results presented in this paper support the neuroprotective effects of low long-term caffeine exposure to epileptic damage and suggest that the increase in the cerebral GSH content caused by caffeine supplementation may provide a new therapeutic approach to the control of seizure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Buthionine Sulfoximine / pharmacology
  • Caffeine / pharmacology*
  • Central Nervous System Stimulants / pharmacology*
  • Convulsants*
  • Electroencephalography / drug effects
  • Enzyme Inhibitors / pharmacology
  • Fluoresceins
  • Fluorescent Dyes
  • Glutathione / metabolism
  • Male
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Nerve Tissue Proteins / metabolism
  • Oxidation-Reduction
  • Oxidative Stress / drug effects*
  • Pentylenetetrazole*
  • Rats
  • Rats, Wistar
  • Seizures / chemically induced*
  • Seizures / prevention & control*
  • Sodium-Potassium-Exchanging ATPase / metabolism
  • Thiobarbituric Acid Reactive Substances / metabolism

Substances

  • Antioxidants
  • Central Nervous System Stimulants
  • Convulsants
  • Enzyme Inhibitors
  • Fluoresceins
  • Fluorescent Dyes
  • Nerve Tissue Proteins
  • Thiobarbituric Acid Reactive Substances
  • diacetyldichlorofluorescein
  • Caffeine
  • Buthionine Sulfoximine
  • Sodium-Potassium-Exchanging ATPase
  • Glutathione
  • Pentylenetetrazole